Unfortunately, ABCB1-mediated resistance is the reason for the major failure of ovarian cancer treatment with paclitaxel, doxorubicin, and PARPi, such as olaparib or rucaparib [7,8,9]. Here, ABCB1 is linked to ovarian carcinoma.